Precision Biosciences Inc key statistics and ratios

In fiscal 2025, Precision Biosciences Inc had return on equity of -61.5%, an operating margin of -152.2%, debt equal to 0.0% of equity and a current ratio of 13.32. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Precision Biosciences Inc: financial ratios, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Operating margin	−440.2%	−8.1%	−452.2%	−34.1%	−248.3%	−89.8%	−38.1%	−152.2%	−80.3%
Net margin	−423.0%	−8.7%	−448.9%	−26.5%	−444.8%	−125.8%	10.4%	−133.4%	−85.6%
Free-cash-flow margin	−606.5%	−8.9%	−380.6%	−13.8%	−195.5%	−176.6%	−85.4%	−192.4%	−115.0%
Return on equity	−115.2%	−104.2%	−119.3%	−45.1%	−147.3%	−154.7%	19.0%	−61.5%	−53.5%
Return on assets	−33.2%	−49.7%	−56.6%	−16.9%	−49.7%	−30.8%	4.8%	−31.4%	−28.1%
Asset turnover	0.08	5.72	0.13	0.64	0.11	0.24	0.46	0.24	0.33
Current ratio	8.22	7.19	2.46	4.50	3.34	2.73	6.34	13.32	10.47
Debt to equity	0.0%	0.0%	0.0%	2.7%	36.8%	—	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	—	n/m	—	n/m	n/m	n/m	n/m	n/m	n/m
Effective tax rate	—	—	—	—	—	—	0.0%	—	—
R&D as % of revenue	414.6%	7.7%	403.8%	99.7%	183.8%	109.5%	86.7%	158.1%	117.0%
Capital spending as % of revenue	131.2%	2.3%	20.7%	4.4%	13.2%	4.0%	0.4%	0.2%	0.1%
Free cash flow ÷ net income	—	—	—	—	—	—	−819.0%	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Precision Biosciences Inc: financial ratios, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Operating margin	<−999%	<−999%	<−999%	<−999%	36.6%	−83.7%	—	—
Net margin	<−999%	<−999%	<−999%	<−999%	58.9%	−170.2%	—	—
Free-cash-flow margin	<−999%	<−999%	<−999%	<−999%	−32.9%	−110.3%	—	—
Current ratio	6.34	6.62	5.18	3.45	13.32	14.02	12.82	10.47
R&D as % of revenue	>999%	>999%	>999%	>999%	42.3%	121.0%	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · September 30, 2026

What it owns · $120m

Short-term assets $87mLonger-term assets $34m

What it owes, and who funded it · $120m

Short-term liabilities $8mLonger-term liabilities $60mShareholders' equity $52m

Short-term assets cover short-term liabilities $87m of assets due within a year against $8m of liabilities due within a year.
Short-term assets cover long-term liabilities $87m short-term assets against $60m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$36m against $1m of interest.

From Precision Biosciences Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

8 /100

Weak moat

How hard Precision Biosciences's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -36.2% of total assets over 8 years.
Durability 10 / 20

Operating margin has been a median -79.3%; its worst year was -12822.6%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 8 years, at a median -153.3% of revenue.
Discipline 0 / 20

The diluted share count rose 813.3% over five years; stock-based pay has been a median 24.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: DTIL vs STRO DTIL vs SPRO DTIL vs EDIT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Precision Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Precision Biosciences Inc.